| ID Source | ID |
|---|---|
| PubMed CID | 66524416 |
| SCHEMBL ID | 6859269 |
| MeSH ID | M0121148 |
| Synonym |
|---|
| cefuroxime axetil |
| 64544-07-6 |
| AKOS015966892 |
| SCHEMBL6859269 |
Cefuroxime axetil is an effective antimicrobial for uncomplicated pediatric UTIs. It penetrates sinus tissue in concentrations exceeding the MIC90 values for pathogens most commonly associated with acute sinusitis, including Streptococcus pneumoniae and Haemophilus influenzae.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cefuroxime Axetil (CA) is a poorly soluble, broad spectrum antibiotic which undergoes enzymatic degradation in gastrointestinal tract. " | ( Preparation and evaluation of cefuroxime axetil gastro-retentive floating drug delivery system via hot melt extrusion technology. Bandari, S; Lalge, R; Maurya, A; Murthy, SN; Pimparade, M; Repka, MA; Shankar, VK; Thipsay, P; Zhang, F, 2019) | 2.25 |
| "Cefuroxime axetil is a new orally absorbed prodrug of the antibiotic cefuroxime. " | ( Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers. Ayrton, J; Harding, SM; Williams, PE, 1984) | 1.71 |
| "Cefuroxime axetil is an effective antimicrobial for uncomplicated pediatric UTIs." | ( Two-day therapy with cefuroxime axetil is effective for urinary tract infections in children. Collins, JJ; Feld, LG; Kornberg, AE; Mydlow, PK; Sherin, K; Veiga, P, 1994) | 1.33 |
| "Cefuroxime axetil is a beta-lactamase-stable, second-generation, oral cephalosporin that penetrates sinus tissue in concentrations exceeding the MIC90 values (the minimum concentration of drug needed to inhibit the growth of 90% of an isolate of a particular microorganism) for pathogens most commonly associated with acute sinusitis, including Streptococcus pneumoniae and Haemophilus influenzae. " | ( Cefuroxime axetil in the treatment of sinusitis. A review. Collins, JJ; Graham, JA; Pakes, GE; Rauch, AM, 1994) | 3.17 |
| "Cefuroxime axetil is an oral cephalosporin which is rapidly hydrolysed to the active parent compound, cefuroxime. " | ( Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Brogden, RN; Perry, CM, 1996) | 3.18 |
| "Cefuroxime axetil is a prodrug of cefuroxime and has little, if any, antibacterial activity until hydrolyzed in vivo to cefuroxime." | ( Nonlinear intestinal absorption kinetics of cefuroxime axetil in rats. Casabo, VG; Merino, M; Nacher, A; Ruiz-Balaguer, N, 1997) | 1.28 |
| "Cefuroxime axetil is a broad spectrum antibacterial agent with a pharmacokinetic profile that permits convenient twice-daily administration. " | ( Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Goa, KL; Ormrod, D; Scott, LJ, 2001) | 3.2 |
| "Cefuroxime axetil is a mixture of two equally active isomers (50% each). " | ( Stability of cefuroxime axetil in suspensions. Bethea, C; Das Gupta, V; Pramar, Y; Zerai, T, 1991) | 2.09 |
| "Cefuroxime axetil (C.A.E.) is a broad spectrum cephalosporin, suitable for oral route. " | ( [Cefuroxime axetil, a new oral cephalosporin for treating infections of the ORL field: clinical synthesis]. Westphal, JF, 1990) | 2.63 |
| "Cefuroxime axetil is a safe and effective oral antimicrobial for the treatment of pneumonia in adults." | ( A multicenter trial comparing the efficacy and safety of cefuroxime axetil and cefaclor in pneumonia of adults. Anthony, W; Lowe, J; Nolen, TM; Schleupner, C; Tan, JS; Yangco, BG, ) | 1.1 |
| "Cefuroxime axetil is a valuable therapy for the treatment of urinary tract infection particularly when due to beta-lactamase producing bacteria." | ( Treatment of acute uncomplicated urinary tract infections with single daily doses of cefuroxime axetil. Harris, K; Joy, GE; Leigh, DA; Tait, S; Walsh, B, 1989) | 1.22 |
| "Cefuroxime axetil is a orally active prodrug formulation of cefuroxime, which upon absorption undergoes immediate deesterification to free cefuroxime. " | ( Cefuroxime axetil. Fant, WK; Marx, MA, 1988) | 3.16 |
| "Cefuroxime axetil is an ester pro-drug which permits the oral administration of cefuroxime. " | ( Effect of dose and food on the bioavailability of cefuroxime axetil. Chubb, J; Finn, A; Meyer, M; Straughn, A, ) | 1.83 |
| "Cefuroxime axetil (CAE) is an acetoxyethyl ester prodrug of cefuroxime. " | ( Cefuroxime axetil in the treatment of uncomplicated UTI: a comparison with cefaclor and augmentin. Brown, GW; Cox, DM; Hebblethwaite, EM; Plested, SJ; Williams, KJ, 1987) | 3.16 |
| "Cefuroxime axetil (CAE) is a prodrug of cefuroxime which is suitable for oral administration, being hydrolysed by non-specific esterases to release cefuroxime (CXM) into the bloodstream. " | ( A dose-ranging study of cefuroxime axetil in the treatment of lower respiratory tract infections in general practice. Brown, GW; Griggs, JV; Spencer, RC, 1987) | 2.02 |
Cefuroxime axetil has been shown to have efficacy comparable to doxycycline in adults with early Lyme disease (LD)
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cefuroxime axetil has been evaluated previously in the treatment of lower respiratory tract infections, but not specifically in the treatment of community-acquired pneumonia. " | ( Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. Collins, JJ; Feris, J; Giguere, G; Hidalgo, H; Higuera, F, 1996) | 2.07 |
| "Cefuroxime axetil has been associated with few reported adverse effects. " | ( Bilateral renal cortical necrosis associated with cefuroxime axetil. Bailie, GR; Eisele, G; Manley, HJ, 1998) | 2 |
| "Cefuroxime axetil has been shown to have efficacy comparable to doxycycline in adults with early Lyme disease (LD). " | ( Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Childs, JA; Eppes, SC, 2002) | 2.08 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cefuroxime axetil treatment gave a significantly higher bacteriological eradication rate and clinical cure rate than PcV." | ( Is penicillin the appropriate treatment for recurrent tonsillopharyngitis? Results from a comparative randomized blind study of cefuroxime axetil and phenoxymethylpenicillin in children. The Swedish Study Group. Grahn, E; Henning, C; Holm, S; Lomberg, H; Staley, H, 1995) | 1.22 |
There were slightly more adverse events in the moxifloxacin group than in the cefuroxime axetil group. Thirteen out of 181 (7%) patients treated with cefura-axetil experienced drug-related adverse events, including 4% with diarrhoea.
| Excerpt | Reference | Relevance |
|---|---|---|
| " These pharmacokinetic data can be used as a basis to compare the four oral cephalosporins; however, comparative susceptibility data must also be considered." | ( Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers. Affrime, MB; Hyatt, JM; Nix, DE; Reidenberg, P; Symonds, WT; Teal, MA; Wilton, JH, ) | 0.36 |
| "The objectives of this study were to determine the oral bioavailability of cefuroxime (C) and to evaluate the pharmacokinetic model that best describes the plasma concentration behaviour following single intravenous (IV), intraperitoneal (IP) and oral single doses." | ( Pharmacokinetics and absolute bioavailability of oral cefuroxime axetil in the rat. Casabo, VG; Merino-Sanjuan, M; Nacher, A; Ruiz-Carretero, P, 2000) | 0.56 |
| " The population pharmacokinetic parameters were obtained by means of nonlinear mixed effect modelling approach according to a nonlinear elimination and nonlinear absorption two-compartment model." | ( Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime. Casabó, VG; Merino-Sanjuán, M; Nácher, A; Ruiz-Carretero, P, 2004) | 0.57 |
| " After a 21 day period of recovery of the malnourished groups a second pharmacokinetic study was performed using the same sample times as in the first study." | ( Effect of malnutrition on the pharmacokinetics of cefuroxime axetil in young rats. González-Hernández, I; Jung-Cook, H; Sotelo, A, 2008) | 0.6 |
| " In the second pharmacokinetic study although the animals received a good quality diet, it was observed that the area under the curve of group K was lower, and the relative bioavailability was 54." | ( Effect of malnutrition on the pharmacokinetics of cefuroxime axetil in young rats. González-Hernández, I; Jung-Cook, H; Sotelo, A, 2008) | 0.6 |
| " We are not aware of a population pharmacokinetic (PK) model for cefuroxime axetil." | ( New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics. Bulitta, JB; Holzgrabe, U; Kinzig, M; Landersdorfer, CB; Sorgel, F, 2009) | 0.82 |
| "The methodology included: (i) dosing regimen selection and acquisition of pharmacokinetic data; (ii) microbiological data acquisition; and (iii) Monte Carlo simulation to estimate the PTA (probability of PK/PD target attainment) and CFR (cumulative fraction of response), as indicators of treatment success." | ( Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective. Aguirre-Quiñonero, A; Canut-Blasco, A; Rodríguez-Gascón, A, ) | 0.55 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "To assess the comparative bioavailability of two formulations (250 mg/5 mL suspension) of cefuroxime axetil (CAS 64544-07-6), administered with food, in healthy volunteers of both sexes." | ( Comparative bioavailability of cefuroxime axetil suspension formulations administered with food in healthy subjects. Borges, A; de Cássia Val, L; De Nucci, G; Mendes, GD; Monif, T; Orellana, AM; Patni, AK; Reyar, S; Sereno, D, 2010) | 0.87 |
The administration of cefuroxime axetil with poori and dal-fry may enhance the bioavailability when compared with idly and chutney. The authors compared the effects of amlodipine (AML) on theBioavailability of cephalexin (LEX) and cefurxime Axetil.
| Excerpt | Reference | Relevance |
|---|---|---|
| "In a three-way cross-over study the bioavailability of cefuroxime was determined in 12 healthy volunteers after oral administration of 250 mg as cefuroxime axetil (Elobact; CAS 64544-07-6) in a plain aqueous suspension and as tablets from different batches." | ( Comparative investigations on the bioavailability of cefuroxime axetil. Grobecker, H; Kees, F; Lukassek, U; Naber, KG, 1991) | 0.73 |
| " The bioavailability of cefuroxime axetil was low due to being administered in the fasting state." | ( Comparison of the serum and tissue concentrations of cefuroxime from cefuroxime axetil and phenoxymethylpenicillin in patients undergoing tonsillectomy. Jetlund, O; Thurmann-Nielsen, E; Walstad, RA, 1991) | 0.82 |
| "A randomized cross-over study comparing serum and urinary concentrations of cefuroxime after a 750 mg intravenous dose of cefuroxime and a 500 mg oral dose of cefuroxime axetil was conducted to evaluate the bioavailability of the current marketed formulation of cefuroxime axetil." | ( Bioavailability of cefuroxime axetil: comparison of standard and abbreviated methods. Davey, PG; Lang, CC; Moreland, TA, 1990) | 0.8 |
| " This study was designed to evaluate the dose proportionality of four different doses administered after a meal and to determine the absolute bioavailability of cefuroxime axetil administered with and without food." | ( Effect of dose and food on the bioavailability of cefuroxime axetil. Chubb, J; Finn, A; Meyer, M; Straughn, A, ) | 0.58 |
| " Recent work has led to the development of cefuroxime axetil (CXM-AX, SN407) which is the 1-acetoxyethyl ester of CXM is well absorbed from the gastrointestinal tract and promptly cleaved to cefuroxime thereafter." | ( [Clinical studies on cefuroxime axetil in acute mastitis]. Hashimoto, I; Mikami, J; Nakamura, T; Sawada, Y, 1987) | 0.85 |
| " The bioavailability of cefuroxime axetil was significantly enhanced in children by the concomitant ingestion of cefuroxime axetil and infant formula or whole milk." | ( Pharmacokinetics and bactericidal activity of cefuroxime axetil. Ginsburg, CM; McCracken, GH; Olson, K; Petruska, M, 1985) | 0.83 |
| " Studies of the pharmacokinetics of the drug in volunteers gave inconsistent results suggesting that there may be variable bioavailability of the compound." | ( Oral cefuroxime axetil: clinical pharmacology and comparative dose studies in urinary tract infection. Adams, DH; Ball, AP; Farrell, ID; Fox, C; Wood, MJ, 1985) | 0.78 |
| "The present study was designed to investigate the effect of food and of a raised intragastric pH on the bioavailability of two prodrug beta-lactam, antibiotics, namely bacampicillin and cefuroxime axetil." | ( Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Moncrieff, J; Schoeman, HS; Sommers, DK; van Wyk, M, 1984) | 0.68 |
| " The bioavailability as measured by urinary recovery of cefuroxime was 40 to 50% if the drug was taken after food and 30% if the drug was taken after overnight fasting." | ( Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers. Ayrton, J; Harding, SM; Williams, PE, 1984) | 0.27 |
| " Pharmacokinetics were studied in 8 volunteers (CAE versus ampicillin), relative bioavailability and tolerance were studied in 100 volunteers (CAE versus pivmecillinam and CAE versus pivampicillin), and tolerance alone was studied in 50 volunteers (CAE versus ampicillin)." | ( Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing. Harding, SM; Sommers, DK; Van Wyk, M; Williams, PE, 1984) | 0.55 |
| " The effect of concomitant use of a phosphate binder on the bioavailability of cefuroxime-axetil was studied in 7 continuous ambulatory peritoneal dialysis (CAPD) patients who had not recently suffered from peritonitis." | ( Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. Brink, HS; de Jong, PE; Geerlings, W; Huisman, RM, 1994) | 0.29 |
| "Betalactams, mainly when orally administered, may lead to intestinal flora modifications related to their spectrum of activity, rate of absorption and degradation." | ( Betalactam therapy and intestinal flora. Cassetta, MI; Conti, S; Dei, R; Fallani, S; Mazzei, T; Novelli, A, 1995) | 0.29 |
| " The cefuroxime front the crystal form of ester is poorly absorbed and the concentrations of [II] after its application were similar to those observed after of the bigest particles of amorphous form both in vivo and in vitro." | ( Esters of cephalosporins. Part I. Permeability of cefuroxime liberated from its 1-acetoxyethyl ester through biological membranes; influence of the form and size of the ester particles. Gumułka, W; Interewicz, B; Oszczapowicz, I; Sasinowska-Motyl, M; Szelachowska, M; Wiśniewska, I, ) | 0.13 |
| "Physico-chemical and microbiological properties of three different forms (crystalline and two amorphous ones) of the 1-acetoxyethyl ester of cefuroxime and bioavailability after oral administration to rats have been investigated." | ( Esters of cephalosporins. Part II. Differences in the properties of various forms of the 1-acetoxyethyl ester of cefuroxime. Denys, A; Horoszewicz-Małafiej, A; Kuklewicz, C; Małafiej, E; Niedworok, J; Oszczapowicz, I; Sierańska, E; Szelachowska, M, ) | 0.13 |
| " Parameters characterizing absorption of prodrug in free solution were obtained: maximum rate of absorption (Vmax) = 289." | ( Nonlinear intestinal absorption kinetics of cefuroxime axetil in rats. Casabo, VG; Merino, M; Nacher, A; Ruiz-Balaguer, N, 1997) | 0.56 |
| " Thus, the addition of the SLS surfactant to the suspension did not alter the bioavailability of the formulation." | ( Bioavailability of cefuroxime axetil formulations. Donn, KH; James, NC; Powell, JR, 1994) | 0.62 |
| " Such stereoselective differences in both absorption and/or hydrolysis may contribute to the observed oral bioavailability (30-50%) of cefuroxime in vivo." | ( Stereoselective absorption and hydrolysis of cefuroxime axetil diastereomers using the Caco-2 cell monolayer model. Barrett, MA; Hutt, AJ; Lansley, AB; Lawrence, MJ, ) | 0.39 |
| " It is concluded that (i) the Delta2 isomerization does not significantly affect the bioavailability of prodrug esters since enzymatic hydrolysis in the intestinal fluid proceeds mainly to the active Delta3-cephalosporin and (ii) the high degree of stereoselectivity of the enzymatic ester hydrolysis should make it possible to increase the bioavailabilities of certain prodrug esters (CAE, CPD) by using the more stable diasterioisomer." | ( Stability of cephalosporin prodrug esters in human intestinal juice: implications for oral bioavailability. Blouin, RA; Duchene, P; Hofheinz, W; Laneury, JP; Shedlofsky, S; Stoeckel, K, 1998) | 0.3 |
| "The objectives of this study were to determine the oral bioavailability of cefuroxime (C) and to evaluate the pharmacokinetic model that best describes the plasma concentration behaviour following single intravenous (IV), intraperitoneal (IP) and oral single doses." | ( Pharmacokinetics and absolute bioavailability of oral cefuroxime axetil in the rat. Casabo, VG; Merino-Sanjuan, M; Nacher, A; Ruiz-Carretero, P, 2000) | 0.56 |
| "The oral bioavailability of cefuroxime axetil is enhanced by food." | ( Effect of two types of Indian breakfast on bioavailability of cefuroxime axetil. Adithan, C; Asad, M; Koumaravelou, K; Shashindran, CH; Topno, I; Vasu, S, 2000) | 0.84 |
| " The values of apparent absorption rate constant, lag-time, Tmax and t1/2 beta for the two regimens were not significantly different." | ( Effect of two types of Indian breakfast on bioavailability of cefuroxime axetil. Adithan, C; Asad, M; Koumaravelou, K; Shashindran, CH; Topno, I; Vasu, S, 2000) | 0.55 |
| "The administration of cefuroxime axetil with poori and dal-fry may enhance the bioavailability when compared with idly and chutney." | ( Effect of two types of Indian breakfast on bioavailability of cefuroxime axetil. Adithan, C; Asad, M; Koumaravelou, K; Shashindran, CH; Topno, I; Vasu, S, 2000) | 0.86 |
| " First-order absorption rate pseudoconstants, k(ap) and effective permeability coefficients, P(eff), were calculated in each set." | ( Intestinal transport of cefuroxime axetil in rats: absorption and hydrolysis processes. Casabo, VG; Merino Sanjuan, M; Nacher, A; Ruiz-Balaguer, N, 2002) | 0.62 |
| " Pharmacokinetics and bioavailability of C in the rat were examined after intravenous (i." | ( Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime. Casabó, VG; Merino-Sanjuán, M; Nácher, A; Ruiz-Carretero, P, 2004) | 0.57 |
| "Many existing and new drugs fail to be fully utilized because of their limited bioavailability due to poor solubility in aqueous media." | ( What is a suitable dissolution method for drug nanoparticles? Chan, HK; Cutler, DJ; Heng, D; Raper, JA; Yun, J, 2008) | 0.35 |
| " The relative bioavailability of cefuroxime was 78." | ( Effect of malnutrition on the pharmacokinetics of cefuroxime axetil in young rats. González-Hernández, I; Jung-Cook, H; Sotelo, A, 2008) | 0.6 |
| "The aim of the present work was to prepare amorphous discreet nanoparticles by sonoprecipitation method for enhancing oral bioavailability of cefuroxime axetil (CA), a poorly water-soluble drug." | ( Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability. Biradar, SV; Dhumal, RS; Paradkar, AR; Yamamura, S; York, P, 2008) | 0.85 |
| " The formulations were characterized by differential scanning calorimetry, X-ray powder diffraction, scanning electron microscopy and Fourier transform infrared spectroscopy studies, and compared for solubility, dissolution and bioavailability in rats." | ( Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability. Aher, S; Biradar, SV; Dhumal, RS; Paradkar, AR, 2009) | 1.8 |
| " However, SDCAGA showed superior bioavailability compared to SDCAP, ACA and CA." | ( Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability. Aher, S; Biradar, SV; Dhumal, RS; Paradkar, AR, 2009) | 1.8 |
| "Improvement in physical stability of solid dispersions was attributed to hydrogen bonding, while improvement in bioavailability of SDCAGA compared to SDCAP, in spite of comparable solubility and dissolution profile, may be attributed to Gelucire, which utilizes intestinal esterase for lipolysis, protecting the prodrug from enzymatic degradation to its non-absorbable base form." | ( Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability. Aher, S; Biradar, SV; Dhumal, RS; Paradkar, AR, 2009) | 1.8 |
| "To assess the comparative bioavailability of two formulations (250 mg/5 mL suspension) of cefuroxime axetil (CAS 64544-07-6), administered with food, in healthy volunteers of both sexes." | ( Comparative bioavailability of cefuroxime axetil suspension formulations administered with food in healthy subjects. Borges, A; de Cássia Val, L; De Nucci, G; Mendes, GD; Monif, T; Orellana, AM; Patni, AK; Reyar, S; Sereno, D, 2010) | 0.87 |
| " The bioavailability study was carried out for 24 healthy male volunteers." | ( Comparative bioavailability study of cefuroxime axetil (equivalent to 500 mg cefuroxime/tablet) tablets (Zednad® versus Zinnat®) in healthy male volunteers. Al-Hadiya, BM; Al-Khamis, KI; Asiri, YA; El-Sayed, YM; Kadi, AA; Mowafy, HA, 2011) | 0.64 |
| " The best formulation (F10) was selected based on in vitro characteristics and used in vivo radiographic and bioavailability studies in healthy human volunteers." | ( Development of gastroretentive drug delivery system for cefuroxime axetil: in vitro and in vivo evaluation in human volunteers. Bomma, R; Veerabrahma, K, ) | 0.38 |
| "To have advantages of reduced dosing frequency, improved bioavailability and effective delivery system of Cefuroxime Axetil, a Chitosan based intragastric sustained release microbead formulation of Cefuroxime Axetil was developed." | ( Chitosan-based intragastric delivery of cefuroxime axetil: development and in-vitro evaluation of mucoadhesive approach. Nagar, M; Yadav, AV, 2012) | 0.86 |
| "The aim of the study was to investigate the bioavailability of a generic product of 500 mg cefuroxime axetil film-coated tablets (test) as compared to that of a branded product (reference) at the same strength to determine bioequivalence and to apply for regulatory approval." | ( Bioequivalence study of 500 mg cefuroxime axetil film-coated tablets in healthy volunteers. Drewniak, T; Gutkowska, A; Gutkowskpi, P; Kaza, M; Ksycińska, H; Leś, A; Piatkowska-Chabuda, E; Rudzki, PJ; Serafin-Byczak, K; Skowrońska-Smolak, M; Tarasiuk, A; Wilkowska, E, ) | 0.64 |
| "In this study, the authors compared the effects of amlodipine (AML) on the bioavailability of cephalexin (LEX) and cefuroxime axetil (CXM)." | ( Effects of amlodipine on the oral bioavailability of cephalexin and cefuroxime axetil in healthy volunteers. Ding, L; Ding, Y; Jia, Y; Jin, X; Liu, W; Lu, C; Song, Y; Wen, A; Yang, J; Yang, L; Zhu, Y, 2013) | 0.84 |
| " In vivo bioavailability study in albino rabbits showed three times improvement in oral bioavailability." | ( Design and characterization of cefuroxime axetil biphasic floating minitablets. Dinda, SC; Jammula, S; Nayak, S; Panigrahi, KC; Patra, ChN; Rao, ME; Swain, S, 2015) | 0.7 |
A new simple high-performance thin layer chromatographic method for determination of cefuroxime axetil and ornidazole in combined tablet dosage form is developed. The goal of this study is to assess, by means of pharmacokinetic/pharmacodynamic (PK/PD) analysis using the Monte Carlo simulation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Each drug was given at a dosage of 30 mg/kg of body weight per day in two divided doses." | ( Evaluation of cefuroxime axetil and cefadroxil suspensions for treatment of pediatric skin infections. Brown, WD; Chartrand, S; Darden, P; Drehobl, MA; Jacobs, RF; Ossi, MJ; Yetman, R, 1992) | 0.64 |
| " Bacterial numbers were reduced by 3 log10 cfu/mL during the eight-hour experimental period with both dosage form simulations." | ( Killing kinetics of cefuroxime axetil against Haemophilus influenzae in an in-vitro model simulating serum concentration profiles after oral administration. Bingen, E; Doit, C; Duvignaud, P; Georges, D; Lambert-Zechovsky, N; Mariani-Kurkdjian, P, 1991) | 0.6 |
| " The data suggest that the standard dosage regimen is adequate in the sick elderly patient." | ( The pharmacokinetics of cefuroxime axetil in the sick elderly patient. Bielawska, C; Kelsey, MC; Rai, G; Ridgway, E; Stewart, K, 1991) | 0.59 |
| " With the recommended dosing regimens (cefuroxime axetil at 250 mg and cefaclor at 375 mg twice daily or cefaclor at 250 mg three times daily), cefuroxime concentrations exceed the MIC for 90% of the strains tested for a greater time period than cefaclor concentrations with either regimen." | ( Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens. Collins, JJ; Davis, IM; Donn, KH; Hart, RW; James, NC; Lloyd, TL; Powell, JR, 1991) | 0.87 |
| " No significant difference in clinical efficacy or adverse events was found between the two dosage regimens." | ( A large scale, general practice based investigation into the clinical efficacy and tolerability of cefuroxime axetil in women with uncomplicated urinary tract infection. Bulpitt, D; Jaderberg, M; Potter, CE, 1991) | 0.5 |
| " The urine recovery after oral dosage and urine bioavailability were 38." | ( Bioavailability of cefuroxime axetil: comparison of standard and abbreviated methods. Davey, PG; Lang, CC; Moreland, TA, 1990) | 0.61 |
| " All volunteers were dosed with both bacampicillin and cefuroxime axetil under the above regimens." | ( Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Moncrieff, J; Schoeman, HS; Sommers, DK; van Wyk, M, 1984) | 0.74 |
| " The kinetic behavior of cefuroxime axetil and ampicillin was not influenced by repeated dosing at 250 mg." | ( Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers. Ayrton, J; Harding, SM; Williams, PE, 1984) | 0.57 |
| " Based on these data, modification of dosing schedule is not deemed necessary when Clcr is above 50 mL/min/1." | ( Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function. Hayashi, M; Konishi, K; Saruta, T; Suzuki, H, 1993) | 0.61 |
| "Cefuroxime axetil (CA) was encapsulated in pH-sensitive acrylic microspheres in order to formulate a suspension dosage form." | ( Development of a microencapsulated form of cefuroxime axetil using pH-sensitive acrylic polymers. Alonso, MJ; Cuña, M; Lorenzo-Lamosa, ML; Torres, D; Vila-Jato, JL, ) | 1.84 |
| " In conclusion, the findings of this study support the use of a bd dosing schedule of cefuroxime in a sequential therapy regimen with oral cefuroxime axetil, demonstrating it to be clinically equivalent to the standard tds dosage currently used, as well as being simpler and more convenient to administer at a lower cost." | ( Sequential therapy with cefuroxime followed by cefuroxime axetil in acute exacerbations of chronic bronchitis. Droszcz, W; Marr, C; Reisenberg, K; Staley, H; Vogel, F; Vondra, V, 1997) | 0.76 |
| " The clinical and bacteriological efficacies and pharmacokinetic properties of both the dosage forms were estimated." | ( [Stepwise therapy of community-acquired pneumonia. Results of cefuroxime and cefuroxime axetil study]. Dvoretskiĭ, LI; Iakovlev, SV; Shakhova, TV; Suvorova, MP; Vlasenko, NA, 1998) | 0.53 |
| " The serum concentrations of cefuroxime were found to be above the minimal inhibitory concentration (MIC) for penicillin-sensitive Streptococcus pneumoniae for 100% of the dosing interval and 42% of the time for intermediate-resistant strains." | ( Measuring antibiotic levels in otitis media. Thoroddsen, E, 1998) | 0.3 |
| " Results showed that SBA was maintained for 100% of the dosing interval for clarithromycin and 50-100% for azithromycin regardless of PCN susceptibility when standard doses were employed." | ( Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae. Lacy, MK; Nicolau, DP; Nightingale, CH; Owens, RC; Quintiliani, R; Xu, X, 1998) | 0.3 |
| " A greater number of infections were eradicated by levofloxacin than by cefuroxime axetil: infections were eradicated in 68% of patients receiving the 500 mg dosage and in 63% of those taking 250 mg levofloxacin, whereas the eradication rate with the comparator drug was much lower (48%)." | ( Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. Davies, BI; Maesen, FP, 1999) | 0.54 |
| "Twenty subjects, selected for surgery because of chronic rhinosinusitis, were randomly allocated to receive either a short (3-8 d) or a long (9-14 d) preoperative treatment regime with 500 mg cefuroxime axetil BID, the last dosage being taken 3 to 4 hours before surgery." | ( Penetration of cefuroxime into chronically inflamed sinus mucosa. Dinis, PB; Gomes, A; Lobato, R; Martins, ML; Monteiro, MC, 1999) | 0.49 |
| " The results suggest that new short-course dosing regimens are viable and may be favourable in terms of increased tolerability, reduction in healthcare costs, enhanced patient compliance and the control of the development of antibiotic resistance." | ( Short-course antibiotic therapy for infections with a single causative pathogen. Adam, D, 2000) | 0.31 |
| " Cefuroxime axetil proved effective as a component of intravenous/oral sequential therapy in the treatment of CAP, although there are currently no dosage recommendations available for this regimen in some countries." | ( Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Goa, KL; Ormrod, D; Scott, LJ, 2001) | 2.66 |
| " This randomized, unblinded study compared 2 dosage regimens of cefuroxime axetil (20 mg/kg/d and 30 mg/kg/d) with amoxicillin (50 mg/kg/d), each given for 20 days." | ( Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Childs, JA; Eppes, SC, 2002) | 0.87 |
| " Three decision trees for solid oral dosage forms or liquid suspensions are provided for evaluating when and how polymorphs of drug substances should be monitored and controlled in ANDA submissions." | ( Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). Adams, RC; Furness, MS; Gill, DS; Holcombe, FO; Raw, AS; Yu, LX, 2004) | 0.32 |
| " In conclusion, an amorphous or non-crystalline CA solid dispersion prepared using SEDS could be very useful for the formulation of solid dosage forms." | ( Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids. Hwang, SJ; Jo, GH; Jun, SW; Kim, MS; Lee, S; Park, JS; Woo, JS, 2005) | 1.77 |
| " Stereo and structural isomers of cefuroxime axetil (CA), anti-cefuroxime axetil (ACA) and Delta(3)-cefuroxime axetil (DCA), can be present in cefuroxime dosage forms as the process related impurities as well as possible degradation product." | ( A stability indicating assay method for cefuroxime axetil and its application to analysis of tablets exposed to accelerated stability test conditions. Ivana, I; Ljiljana, Z; Mira, Z, 2006) | 0.88 |
| " The work indicates an approach to design pH-sensitive polymers for dosage forms that meet the pharmacokinetic requirements of the drug." | ( Designing a self-associated cationic polymer for enhanced compatibility, palatability, and gastric release of cefuroxime axetil. Kulkarni, MG; Menjoge, AR, 2007) | 0.55 |
| " It is crucial that the dissolution behavior of such novel dosage forms be adequately scrutinized to maximize their therapeutic benefits." | ( Dissolution kinetic behavior of drug nanoparticles and their conformity to the diffusion model. Chan, HK; Cutler, DJ; Heng, D; Raper, JA; Yun, J, 2008) | 0.35 |
| "A simple, accurate and sensitive reversed-phase high performance liquid chromatographic (RP-HPLC) method for the simultaneous determination of cefuroxime axetil and ornidazole in combined tablet dosage form has been developed." | ( Simultaneous determination of cefuroxime axetil and ornidazole in tablet dosage form using reversed-phase high performance liquid chromatography. Gandhi, SV; Kadukar, SS; Ranher, SS; Ranjane, PN, 2008) | 0.84 |
| "A new simple high-performance thin layer chromatographic method for determination of cefuroxime axetil and ornidazole in combined tablet dosage form is developed and validated." | ( HPTLC determination of cefuroxime axetil and ornidazole in combined tablet dosage form. Bothara, KG; Gandhi, SV; Kadukar, SS; Ranjane, PN, 2010) | 0.9 |
| "To have advantages of reduced dosing frequency, improved bioavailability and effective delivery system of Cefuroxime Axetil, a Chitosan based intragastric sustained release microbead formulation of Cefuroxime Axetil was developed." | ( Chitosan-based intragastric delivery of cefuroxime axetil: development and in-vitro evaluation of mucoadhesive approach. Nagar, M; Yadav, AV, 2012) | 0.86 |
| " For amoxicillin and amoxicillin/clavulanate, the target was free antibiotic concentration remaining above the minimum inhibitory concentration (MIC) for ≥50% of the dosing interval (fT>MIC≥50%), whereas for cefuroxime axetil and cefotaxime, the target was fT>MIC≥60%." | ( Application of pharmacokinetic/pharmacodynamic analysis to evaluate the adequacy of antimicrobial therapy for pediatric acute otitis media in Spain before and after the introduction of the PCV7 vaccine. Canut-Blasco, A; Ibar-Bariain, M; Isla, A; Rodríguez-Gascón, A; Solinís, MA, 2019) | 0.7 |
| "The goal of this study is to assess, by means of pharmacokinetic/pharmacodynamic (PK/PD) analysis using the Monte Carlo simulation, the adequacy of oral cephalosporins cefuroxime axetil, cefixime and cefditoren at different dosing regimens as switch therapy after intravenous cephalosporin treatment in uncomplicated acute pyelonephritis." | ( Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective. Aguirre-Quiñonero, A; Canut-Blasco, A; Rodríguez-Gascón, A, ) | 0.74 |
| "The methodology included: (i) dosing regimen selection and acquisition of pharmacokinetic data; (ii) microbiological data acquisition; and (iii) Monte Carlo simulation to estimate the PTA (probability of PK/PD target attainment) and CFR (cumulative fraction of response), as indicators of treatment success." | ( Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective. Aguirre-Quiñonero, A; Canut-Blasco, A; Rodríguez-Gascón, A, ) | 0.55 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 48 (16.72) | 18.7374 |
| 1990's | 126 (43.90) | 18.2507 |
| 2000's | 79 (27.53) | 29.6817 |
| 2010's | 31 (10.80) | 24.3611 |
| 2020's | 3 (1.05) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (96.45) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 133 (40.30%) | 5.53% |
| Reviews | 23 (6.97%) | 6.00% |
| Case Studies | 22 (6.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 152 (46.06%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Oropharyngeal Microorganism Colonization on the Peristomal Infection After Percutaneous Endoscopic Gastrostomy and the Effect of Tailored Antibiotics Prophylaxis [NCT01237730] | 100 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | |||
| Introduction of Nitrofurantoin in Place of Ciprofloxacin in Patients of Uncomplicated Urinary Tract Infection: a Controlled Clinical Trial to Establish the Relationship Between Revival and Associated Shift in Sensitivity Pattern of the Causative Microbes [NCT03716804] | Phase 4 | 62 participants (Actual) | Interventional | 2018-06-06 | Completed | ||
| Effects of Applying Powdered Prophylactics Verses Intravenous Antibiotics Only on Post-operative Infection Rate [NCT01372371] | 1,844 participants (Anticipated) | Interventional | 2011-06-30 | Recruiting | |||
| Antibiotic Prophylaxis for Postpartum Infections Following Caesarean Section [NCT02072798] | Phase 4 | 42 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240] | Early Phase 1 | 11 participants (Actual) | Interventional | 2014-03-06 | Terminated(stopped due to Not enough patient enrollment and lack of staffing) | ||
| Prospective Randomised Study of Daptomycin as Antibiotic Prophylaxis of Sternal Wound Infections After Median Sternotomy [NCT01080963] | Phase 4 | 650 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Population Pharmacokinetics, Effectiveness and Safety of Cefuroxime in Neonates [NCT05388747] | 100 participants (Anticipated) | Observational | 2022-05-16 | Recruiting | |||
| Perioperative Cefuroxime in Obese Patients: Dosage According to the BMI [NCT03141476] | Phase 4 | 60 participants (Actual) | Interventional | 2017-03-01 | Completed | ||
| Does Antibiotic Prophylaxis at Urinary Catheter Removal Prevent Urinary Tract Infections [NCT05577273] | 1,000 participants (Anticipated) | Interventional | 2018-08-14 | Enrolling by invitation | |||
| Ampicillin / Sulbactam Versus Cefuroxime as Antimicrobial Prophylaxis for Cesarean Section: a Randomized Study [NCT01138852] | Phase 4 | 176 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| A Randomized Controlled Trial: Role of EFTs (Emotional Freedom Techniques) in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy. [NCT02169856] | 50 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Efficacy and Safety of Periarticular Multimodal Drug Injections in Total Knee Arthroplasty [NCT00901628] | Phase 4 | 101 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Comparative Efficacy of Intravenous Cefuroxime and Ceftriaxone in Preventing Surgical Site Infection After Neurosurgical Procedures [NCT05398081] | Phase 2 | 96 participants (Actual) | Interventional | 2021-12-01 | Completed | ||
| An Open Randomized Controlled Study of Bismuth Quadruple Therapy With Cefuroxime as Rescue Therapy for Helicobacter Pylori Infection [NCT04723472] | 82 participants (Anticipated) | Interventional | 2023-08-01 | Suspended(stopped due to Want to modify the study further) | |||
| Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic: A Randomized Controlled Study [NCT04009772] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2019-07-01 | Recruiting | ||
| Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes. A Randomized Prospective, Open Trial [NCT02819570] | Phase 4 | 400 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | ||
| Intracameral Levofloxacin (0.5%) Versus Intracameral Cefuroxime (1mg/0.1ml) Effect on Corneal Endothelial Cell Count and Morphology in Uneventful Phacoemulsification [NCT04212078] | Phase 1/Phase 2 | 138 participants (Anticipated) | Interventional | 2019-07-29 | Recruiting | ||
| An Open, Prospective, Randomized, Multi-Center Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin vs. Cefuroxime Monotherapy or Plus Oral Erythromycin for the Treatment of Chinese Hospitalized Patients With Community- Acquired P [NCT00648726] | Phase 3 | 139 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| The Preventive Urinary Tract Infection Role of One Week Solutions of Antimicrobial Application Before Minimally Invasive Upper Tract Lithotomy [NCT02789579] | Early Phase 1 | 150 participants (Anticipated) | Interventional | 2016-09-30 | Recruiting | ||
| Does Sugared or Sugar Free Chewing Gum Reduces Postoperative Ileus After Laparoscopic Cholecystectomy [NCT02162134] | 90 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| The Effect of Intracameral Cefuroxime on Post-op Fibrin in Pediatric Cataract Surgery [NCT00730938] | 45 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| Pharmacokinetics of Post Operative Cefuroxime in Infants Undergoing Cardiac Surgery [NCT02850250] | 0 participants (Actual) | Observational | 2018-07-31 | Withdrawn(stopped due to CI left the country so study has never opened) | |||
| Effect of Inappropriate Therapy With Cefuroxime in Adult Patients Hospitalized With Pyelonephritis [NCT04616352] | 973 participants (Actual) | Observational | 2020-12-26 | Completed | |||
| Very Short-course Versus Standard Course Antibiotic Therapy in Patients With Acute ChOlangitis After Adequate Endoscopic BiliaRy drAinage [NCT05750966] | 440 participants (Anticipated) | Interventional | 2023-07-19 | Recruiting | |||
| Beta-lactam Monotherapy Versus Beta-lactam - Macrolide Association as Empiric Antibiotherapy Strategies in Non-severe Hospitalized Community-acquired Pneumonia: a Randomized, Non-inferiority, Open Trial. [NCT00818610] | Phase 4 | 601 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Antibiotic Prophylaxis and Intervention for Postpartum Infections Following Caesarean Section [NCT02009098] | Phase 4 | 0 participants (Actual) | Interventional | 2014-10-31 | Withdrawn | ||
| Colo-Pro_2: A Feasibility Randomised Controlled Double Blind Trial to Compare Standard Bolus Dosed Cefuroxime Prophylaxis to Bolus-continuous Infusion Dosed Cefuroxime Prophylaxis for the Prevention of Infections After Colorectal Surgery [NCT05609240] | Phase 2 | 180 participants (Anticipated) | Interventional | 2023-05-10 | Recruiting | ||
| A Prospective, Randomized, Blind, Multicenter Trial Comparing Orally Administered Trimethoprim-sulfamethoxazole With Intravenously Administered Cefuroxime and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery [NCT00613769] | Phase 4 | 1,073 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| 24 Versus 48 Hours of First Generation or Second Generation Cephalosporin as Prophylaxis to Reduce Surgical Site Infection in Adult Cardiac Surgery Patients: a Randomized Controlled Trial [NCT04303390] | Phase 4 | 568 participants (Actual) | Interventional | 2018-02-06 | Completed | ||
| Prospective, Double-Blind, Randomized, Placebo-Controlled Trial of Single-Dose Cefuroxime Prophylaxis in Herniated Disk Surgery [NCT00530400] | Phase 4 | 1,369 participants (Actual) | Interventional | 1994-04-30 | Completed | ||
| Antibiotic Prophylaxis for Cataract Surgery Version 7e January 22 2003 [NCT00136344] | 35,000 participants | Interventional | 2003-09-30 | Completed | |||
| Randomised And Double Blind Study To Evaluate The Best Moment To Infuse The Prophylactic Antibiotic In Knee Arthroplasty Performed Under Ischemia [NCT00497341] | Phase 4 | 1,332 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Role of Delay and Antibiotics on PERForation Rate While Waiting appendECTomy - Randomized Non-inferiority Trial [NCT04378868] | Phase 4 | 1,800 participants (Actual) | Interventional | 2020-05-18 | Completed | ||
| Phase 3 Study of Antibiotic Prophylaxis Use Prior Emergent Surgery, Because of Acute Appendicitis [NCT01524081] | Phase 3 | 187 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Management of HIV-Infected Patients at Risk of Recurrent Purulent Sinusitis: Role of Anti-Inflammatory, Antibacterial, and Decongestant Prophylaxis [NCT00000752] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn | |||
| Antibiotikaprofylakse Ved Vaginalplastik [NCT00162604] | 200 participants | Interventional | 2005-05-31 | Recruiting | |||
| Risk Factors for Failure of Erythema Migrans Treatment - Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Adult Patients With Erythema Migrans: Clinical and Microbiological Outcome. [NCT01518192] | Phase 4 | 544 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Standard Versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes After Whipple's Procedure (SPARROW): a Multicenter, Randomized Controlled Trial [NCT05784311] | Phase 4 | 322 participants (Anticipated) | Interventional | 2023-03-06 | Recruiting | ||
| Oral + Parenteral Antibiotic Prophylaxis Before Colonic Surgery With vs Without Mechanical Bowel Preparation: a Prospective, Multicentric, Randomised, Controlled Trial. [NCT04161599] | Phase 4 | 968 participants (Anticipated) | Interventional | 2022-03-01 | Recruiting | ||
| Colo-Pro Pilot: A Pilot Study to Compare Standard Single Dose Antibiotic Prophylaxis to Bolus-continuous Infusion Dosed Antibiotic Prophylaxis for the Prevention of Infections After Colorectal Surgery [NCT02445859] | Phase 2 | 90 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Randomized Controlled Trial to Evaluate the Optimal Timing of Surgical Antimicrobial Prophylaxis [NCT01790529] | Phase 4 | 5,000 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Preoperative Oral Antibiotics and Surgical Site Infections in Colon Surgery Without Mechanical Bowel Preparation. A Prospective, Multicentre, Single Blinded, Randomized Trial (ORALEV Study) [NCT02505581] | Phase 4 | 536 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| The Value of Perioperative Antibiotics on the Success of Oral Free Flap Reconstructions [NCT02436083] | Phase 4 | 350 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Randomized Controlled Study of Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection [NCT04479657] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2020-10-17 | Recruiting | ||
| Infections After Hysterectomy - a Placebo-controlled Study Comparing the Prophylactic Use of Azithromycin and Cefuroxime With Single Cefuroxime [NCT05337566] | 2,278 participants (Anticipated) | Interventional | 2022-09-05 | Recruiting | |||
| Comparison of Doxycycline and Cefuroxime Axetil in Patients With Erythema Migrans [NCT03584919] | 509 participants | Interventional | 2006-06-01 | Completed | |||
| Population Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Septic Patients Admitted to the ICU or the ED [NCT04470973] | 40 participants (Anticipated) | Observational | 2020-07-15 | Recruiting | |||
| 100000 Cases Real World Research of the Safety and Efficacy Revaluation of Cefuroxime Axetil Dispersible Tablets After Listing [NCT03020940] | 100,000 participants (Anticipated) | Observational | 2017-01-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||